February 02, 2016; 86 (5) Special Article
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy
Report of the Guideline Development Subcommittee of the American Academy of Neurology
David Gloss, Richard T. Moxley, Stephen Ashwal, Maryam Oskoui
First published February 1, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002337
David Gloss
From the Department of Neurology (D.G.), Geisinger Health System, Danville, PA; Department of Neurology (R.T.M.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (S.A.), Loma Linda University Medical Center, CA; and Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montréal, Canada.
Richard T. Moxley III
From the Department of Neurology (D.G.), Geisinger Health System, Danville, PA; Department of Neurology (R.T.M.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (S.A.), Loma Linda University Medical Center, CA; and Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montréal, Canada.
Stephen Ashwal
From the Department of Neurology (D.G.), Geisinger Health System, Danville, PA; Department of Neurology (R.T.M.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (S.A.), Loma Linda University Medical Center, CA; and Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montréal, Canada.
Maryam Oskoui
From the Department of Neurology (D.G.), Geisinger Health System, Danville, PA; Department of Neurology (R.T.M.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (S.A.), Loma Linda University Medical Center, CA; and Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montréal, Canada.
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy
Report of the Guideline Development Subcommittee of the American Academy of Neurology
David Gloss, Richard T. Moxley, Stephen Ashwal, Maryam Oskoui
Neurology Feb 2016, 86 (5) 465-472; DOI: 10.1212/WNL.0000000000002337
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
Additional Files
Data Supplement
Guideline with five supplemental tables and Executive Summary references and five supplemental tables; six PDF files.
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2016 American Academy of Neurology.
Files in this Data Supplement:- Guideline - PDF file
- Table e-1 - Guideline - PDF file
- Tables e-2 to e-5 - Guideline - PDF file
- e-References - Executive Summary - PDF file
- Table e-1 - Executive Summary - PDF file
- Tables e-2 to e-5 - Executive Summary - PDF file
Disputes & Debates: Rapid online correspondence
- Authors' response to Dr. Topaloglu's comment
- David Gloss, MD, MPH&TM, Neurologist, Charleston Area Medical Center, Charleston, WVguidelines@aan.com
- Richard T. Moxley III, Neurologist, Rochester, NY; Stephen Ashwal, MD, Neurologist, Loma Linda, CA; Maryam Oskoui, MD, Neurologist, Montreal, Canada
Submitted February 22, 2016 - 0.75 mg/kg prednisone can never be sustained
- Haluk Topaloglu, Faculty, Hacettepe University Children's Hospital, Ankara, Turkeyhtopalog@hacettepe.edu.tr
Submitted February 12, 2016
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement